US Patent Issued to Cullinan Therapeutics on Sept. 30 for "Anti-CD19 antibodies and multi-specific binding proteins" (Massachusetts Inventors)

ALEXANDRIA, Va., Sept. 30 -- United States Patent no. 12,428,480, issued on Sept. 30, was assigned to Cullinan Therapeutics Inc. (Cambridge, Mass.).

"Anti-CD19 antibodies and multi-specific binding proteins" was invented by Patrick A. Baeuerle (Cambridge, Mass.), Jennifer Michaelson (Cambridge, Mass.), Bochong Li (Boston) and Naveen Mehta (Cambridge, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are anti-CD 19 antibodies and multi-specific binding proteins that bind CD 19, CD3, and serum albumin. Also provided are pharmaceutical compositions comprising these antibodies or multi-specific binding proteins, expression vectors and host cells for making these antibodies or multi-specific bi...